Exclusive: Helsinn chief Riccardo Braglia spells out a blockbuster plan to take the family pharma public — with an eye on new cancer drug deals, spinout
Late on Friday, as the biopharma industry in the US was making a rush to the exits for a 3-day weekend, BridgeBio put out word that the FDA had come through on a critical first OK for QED, one of their many subs pushing a drug through clinical development. The agency offered an accelerated approval for Truseltiq (infigratinib), a new therapy for cases of cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.